Recombinant ITGAL (Efalizumab Biosimilar) antibody

Catalog No. ABIN7795106

This Mouse Monoclonal antibody specifically detects ITGAL (Efalizumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant ITGAL (Efalizumab Biosimilar) antibody (ABIN7795106)

Target: ITGAL (Efalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ITGAL (Efalizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-ITGAL (Efalizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Efalizumab Biosimilar, CD11a Monoclonal Antibody

Characteristics: Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD11a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for ITGAL (Efalizumab Biosimilar)

Target: ITGAL (Efalizumab Biosimilar)

Alternative Name: Efalizumab Biosimilar

Target Type: Biosimilar